【0001】
【発明の属する技術分野】
本発明は特定の植物抽出物を含有する美白用皮膚外用剤に関する。本発明の美白用皮膚外用剤はチロシナーゼ活性阻害効果、サイクリックAMP(cAMP)産生阻害効果を併せ持ち、優れたメラニン生成抑制効果、美白効果を有し、かつ安全性に優れたものである。
【0002】
【従来の技術】
皮膚のしみ、そばかす等の色素沈着は、ホルモンの異常分泌、紫外線や炎症性の刺激等により、表皮色素細胞内メラニン産生情報伝達経路が活性化し、メラニン産生主要酵素であるチロシナーゼの産生、活性発現が亢進した結果、メラニンが表皮に過剰に沈着するため生ずる。
【0003】
このようなしみ、そばかすを防ぐ手段として、メラニン産生主要酵素であるチロシナーゼの活性を阻害する物質が従来用いられてきた。具体的にはチロシナーゼ活性発現に必須である銅イオンを捕捉することを作用機序とするコウジ酸、エラグ酸等を配合してなるクリーム、ローション等の局所への塗布や、基質チロシンと類似構造を有し、チロシナーゼ競合阻害剤として働くハイドロキノン誘導体、レゾルシノール誘導体等を配合してなるクリーム、ローション等の局所への塗布、あるいは上記以外の作用機序を有する物としては、メラニン前駆体であるドーパキノンをドーパに還元することをメラニン産生抑制機序とするL−アスコルビン酸の投与が行われてきた。
【0004】
【発明が解決しようとする課題】
前記の物質は産生されたチロシナーゼに対して、またはチロシナーゼ活性発現により産生されたドーパキノンに作用するものであり、チロシナーゼ産生そのものを阻害するものではなかった。そのため、効果自体およびその持続性が弱いという難点があった。また、L−アスコルビン酸に関しては原体および基剤中での安定性が悪く、しみ、そばかすを十分に防ぐ効果を得るためには大量の投与が必要とされている。
【0005】
近年、植物抽出液中に含有される各種の活性成分が注目されている。多くの植物に含有されるポリフェノール類の抗酸化作用を始めとして、抗腫瘍作用等様々の作用が報告されている。美白作用を有する植物抽出液もさまざまなものが探索されている。
美白効果を有する植物として、従来より金桜子、営実、地楡などが知られているが、これらの植物抽出液もまたチロシナーゼ活性を阻害することをその作用機序としたものであり、美白作用およびその持続性は満足できるものではなかった。
一方、情報伝達経路に作用し、メラニンの産生自身を阻害する物質として、一酸化窒素経路阻害作用を有するかきょく、プロテインカイネースC経路阻害作用を有するカミツレ等が報告されている。しかしながらこれらの伝達経路はメラニン産生への関与が低く、顕著なメラニン産生阻害を得ることは困難であり、より優れた植物抽出薬効剤の開発が期待されていた。
また本出願人はバラ科のセイヨウバラがサイクリックAMP(cAMP)の産生を阻害して美白作用を有することをすでに見出している(特開2002−29959)。
【0006】
本発明者らは上記事情に鑑み鋭意研究を重ねた結果、特定の植物およびその抽出物にチロシナーゼ活性阻害効果およびメラニン産生への関与が高いアデニレートサイクレース経路阻害効果を併せ持ち、優れた美白効果、優れたメラニン生成抑制効果があることを見出し、本発明を完成するに至った。
【0007】
【課題を解決するための手段】
すなわち本発明は、ツツジ科 Gaultheria fragranthissima、カタバミ科 Averrhoa carambola (別名:ゴレンシ)、ココヤシ科 Cocos nucifera(別名:ココヤシ,ココナッツ)、マメ科 Desmodium triquetrum、またはこれらの溶媒抽出物を有効成分として含有することを特徴とする美白用皮膚外用剤である。
【0008】
また本発明は、上記植物またはその溶媒抽出物を有効成分として含有することを特徴とするメラニン生成抑制剤、チロシナーゼ活性阻害剤およびサイクリックAMP(cAMP)産生阻害剤が提供される。
【0009】
【発明の実施の形態】
以下、本発明について詳述する。
本発明において用いられるツツジ科 Gaultheria fragranthissima、カタバミ科 Averrhoa carambola (別名:ゴレンシ)、ココヤシ科 Cocos nucifera(別名:ココヤシ,ココナッツ)、マメ科 Desmodium triquetrum は、生のままでも乾燥したものでも使用することができるが、使用性、製剤化等の点から乾燥粉末あるいは溶媒抽出物として用いることが好ましい。
【0010】
それぞれの植物の好ましい使用部位は次の通りである。
即ち、ツツジ科 Gaultheria fragranthissima については葉、カタバミ科 Averrhoa carambola (別名:ゴレンシ)については葉または果実、ココヤシ科 Cocos nucifera (別名:ココヤシ,ココナッツ)については根、マメ科 Desmodium triquetrum については葉または茎を用いるのが好ましいが、他の部位を用いることもできる。
【0011】
上記各植物の溶媒抽出物は常法により得ることができ、例えば、抽出溶媒とともに浸漬または加熱還流した後、濾過し濃縮して得ることができる。抽出溶媒としては、通常抽出に用いられる溶媒であれば任意に用いることができ、例えば、水、メタノール、エタノール、プロピレングリコール、1,3−ブチレングリコール、グリセリン等のアルコール類、含水アルコール類、クロロホルム、ジクロルエタン、四塩化炭素、アセトン、酢酸エチル、ヘキサン等の有機溶媒類等を、それぞれ単独あるいは組み合わせて用いることができる。上記溶媒で抽出して得た抽出液をそのまま、あるいは濃縮したエキスを吸着法、例えばイオン交換樹脂を用いて不純物を除去したものや、ポーラスポリマー(例えばアンバーライトXAD−2)のカラムにて吸着させた後、メタノールまたはエタノールで溶出し、濃縮したものも使用することができる。また分配法、例えば水/酢酸エチルで抽出した抽出物等も用いられる。
【0012】
このようにして得た上記植物抽出物は、安全性が高く、優れた美白効果、メラニン生成抑制効果、チロシナーゼ活性阻害効果およびサイクリックAMP(cAMP)産生阻害効果を有する。
【0013】
上記植物抽出物を皮膚外用剤に配合して用いる場合、外用剤全量中に乾燥重量として0.000001〜5.0質量%配合するのが好ましく、より好ましくは0.00001〜3.0質量%、特に好ましくは0.00001〜1.0質量%である。
【0014】
上記植物抽出物を皮膚外用剤に配合して用いる場合、これら抽出物に加えて、本発明の効果を損なわない範囲内で、通常化粧品や医薬品等の皮膚外用剤に用いられる他の成分、例えば油分、湿潤剤、紫外線吸収剤、酸化防止剤、界面活性剤、防腐剤、保湿剤、香料、水、アルコール、増粘剤等を必要に応じて適宜配合することができる。
【0015】
前項の紫外線吸収剤としては、2−ヒドロキシ−4−メトキシベンゾフェノン、2−ヒドロキシ−4−メトキシベンゾフェノン−5−スルホン酸ナトリウム、ベンゾトリアゾリルブチルフェノールスルホン酸ナトリウム、メチレンビス−ベンゾトリアゾイルテトラメチルブチルフェノール等のベンゾフェノン誘導体、パラメトキシ桂皮酸オクチル、ジパラメトキシ桂皮酸モノ−2−エチルヘキサン酸グリセリル、イソペンチルトリメトキシ桂皮酸トリシロキサン等のメトキシ桂皮酸誘導体、ウロカニン酸、4−tert−4’−メトキシジベンゾイルメタン、ビス−エチルヘキシルオキシフェノールメトキシフェニルトリアジン、エチルヘキシルトリアゾン、フェニルベンジイミダゾールスルホン酸等を必要に応じて適宜配合することができる。
【0016】
さらに、エデト酸二ナトリウム、エデト酸三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリウム、メタリン酸ナトリウム、グルコン酸等の金属イオン封鎖剤、カフェイン、タンニン、ベラパミル、トラネキサム酸およびその誘導体、甘草抽出物、グラブリジン、各種生薬、酢酸トコフェロール、グリチルリチン酸およびその誘導体またはその塩等の薬剤、ビタミンC、アスコルビン酸リン酸マグネシウム、アスコルビン酸グルコシド、アルブチン、コウジ酸、レゾルシノール、エラグ酸、カミツレ抽出物等の他の美白剤、グルコース、フルクトース、マンノース、ショ糖、トレハロース等の糖類等も適宜配合することができる。
【0017】
また、本発明の皮膚外用剤は、外皮に適用される化粧料、医薬品、医薬部外品等、特に好適には化粧料に広く適用することが可能であり、その剤型も、皮膚に適用できるものであればいずれでもよく、溶液系、可溶化系、乳化系、粉末分散系、水−油二層系、水−油−粉末三層系、軟膏、ゲル、エアゾール等、任意の剤型が適用される。
【0018】
また、本発明の皮膚外用剤の使用形態も任意であり、例えば化粧水、乳液、クリーム、パック等のフェーシャル化粧料やファンデーションの他、メーキャップ化粧料、芳香化粧料、浴用剤等に用いることができる。
なお、上記の剤型および使用形態に本発明の皮膚外用剤がとり得る形態が限定されるものではない。
【0019】
【実施例】
次に、実施例を挙げて本発明をさらに詳細に説明するが、本発明の技術的範囲はこれらの実施例によってなんら限定されるものでない。なお、配合量はすべて質量%である。
【0020】
実施例に先立ち、本発明の植物抽出物のチロシナーゼ活性阻害効果、サイクリックAMP(cAMP)産生阻害効果、メラニン生成抑制効果および美白効果について、試験方法と評価方法について説明する。
【0021】
[試験方法および評価方法]
1.試料の調製
(1)Gaultheria fragranthissima 抽出物
Gaultheria fragranthissimaの葉1000gを、80%エタノールを5L用いて加温抽出し、抽出液を得た。この抽出液を濃縮し、Gaultheria fragranthissima 抽出物72.0gを得た。
【0022】
(2)Averrhoa carambola 抽出物
Averrhoa carambola の葉50gを、80%エタノールを1L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Averrhoa carambola 抽出物7.3gを得た。
【0023】
(3)Cocos nucifera 抽出物
Cocos nucifera の根50gを、80%エタノールを1L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Cocos nucifera 抽出物2.3gを得た。
【0024】
(4)Desmodium triquetrum 抽出物
Desmodium triquentrum の葉50gを、80%エタノールを1L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Desmodium triquentrum 抽出物3.5gを得た。
【0025】
上記各植物抽出物を70%エタノールに濃度2質量%となるよう溶解して、植物抽出物含有溶液とした。これら植物抽出物含有溶液を希釈して濃度を調整し、これを試料溶液として用い、以下の実験を行った。
【0026】
2.細胞培養方法
マウス由来のB16メラノーマ培養細胞を使用した。10%FBSおよびテオフィリン(0.09mg/ml)、またはメラノサイト刺激ホルモン(α―MSH)(10nM)を含むダルベッコMEM培地でCO2インキュベーター(95%空気、5%二酸化炭素)内、37℃の条件下で培養した。
【0027】
3.チロシナーゼ活性阻害効果測定
上記2の方法で培養した細胞を96プレートに播種し、培養24時間後に試料溶液を終濃度(抽出乾燥物換算濃度)が10−7〜10−5質量%になるように添加し、さらに培養を続けた。培養3日後PBSを用いて洗浄、1%Triton含有PBSを加え、さらにDOPAを終濃度1mMとなるように加えた。添加0分および60分後の吸光度(475nm)を測定した。植物抽出物を添加していない試料(コントロール;70%エタノール)と比較し、下記判定基準により評価した。また、参考例として、ノバラ(Rosa canina L.)抽出物(エタノール抽出)についても、上記と同様の試験を行った。結果を表1に示す。なお、表1にはメラノサイト刺激ホルモン(α―MSH)を含む培地での結果を示したが、テオフィリンを用いた場合も同様の結果であった。
【0028】
(判定基準)
○:コントロールに比べチロシナーゼ活性阻害作用に優れる。
△:コントロールに比べチロシナーゼ活性阻害作用にやや優れる。
×:チロシナーゼ活性阻害作用なし。
【0029】
【表1】
【0030】
4.メラニン量の視感判定(メラニン生成抑制効果)
前記2の方法で培養した細胞を96プレートに播種し、培養24時間後に試料溶液を終濃度(抽出乾燥物換算濃度)が10−2〜10−5質量%になるように添加し、さらに培養を続けた。培養3日後、96ウェルのプレートの蓋の上に拡散板を置き、倒立顕微鏡で細胞内のメラニン量を観察し、植物抽出物を添加していない試料(コントロール;70%エタノール)と比較し、下記判定基準により評価した。また、参考例として、ノバラ(Rosa canina L.)抽出物(エタノール抽出)についても、上記と同様の試験を行った。結果を表2に示す。なお、表2にはメラノサイト刺激ホルモン(α―MSH)を含む培地での結果を示したが、テオフィリンを用いた場合も同様の結果であった。
【0031】
(判定基準)
○:コントロールに比べ白い(メラニン生成抑制作用に優れる)。
△:コントロールに比べやや白い(メラニン生成抑制作用にやや優れる)。
×:コントロールと同程度の白さ(メラニン生成抑制作用なし)。
【0032】
【表2】
【0033】
5.サイクリックAMP(cAMP)産生阻害効果測定
マウス由来のB16メラノーマ培養細胞を12ウェルプレートに播種し、10%FBSを含むダルベッコMEM培地でCO2インキュベーター(95%空気、5%二酸化炭素)内、37℃の条件下で培養した。培養24時間後に培地を吸引し、メラノサイト刺激ホルモン(α―MSH、0.1nM)、および試料溶液を終濃度10−1〜10−3質量%(抽出乾燥物換算濃度)になるように添加した無血清培地を加えた。30分間インキュベート後、培地を除去し、TEバッファーにて細胞を集め、1.5mLマイクロチューブに移し、煮沸した後、この液中のサイクリックAMP(cAMP)量をサイクリックAMP(cAMP)測定キット(アマシャム社製)を用いて測定した。また、参考例として、バラ科(Rosaceae)バラ属(Rosa)に属するノバラ(Rosa canina L.)抽出物(エタノール抽出)についても、上記と同様の試験を行った。植物抽出物を添加していない試料(コントロール;70%エタノール)と比較し、下記判定基準により評価した。結果を表3に示す。
【0034】
(判定基準)
○:コントロールに比べサイクリックAMP(cAMP)産生阻害作用に優れる。
△:コントロールに比べサイクリックAMP(cAMP)産生阻害剤作用にやや優れる。
×:サイクリックAMP(cAMP)産生阻害作用なし。
【0035】
【表3】
【0036】
6.美白効果試験
(試験方法)
夏期の太陽光に4時間(1日2時間で2日間)曝された被験者20名の背部皮膚を対象として、下記に示す試験試料溶液を朝夕1回ずつ4週間塗布し、下記に示す判定基準により評価を行った。被験者20名の評価点平均値の結果を表4に示す。
【0037】
(製法)
水相、アルコール相をそれぞれ調製後、混合し、可溶化した。
【0038】
(評価方法)
使用後の淡色化効果を下記の判定基準に基づいて判定した。
(評点)
4:連用塗布後、淡色化効果が顕著に認められた。
3:連用塗布後、淡色化効果が認められた。
2:連用塗布後、淡色化効果がやや認められた。
1:連用塗布後、淡色化効果が認められなかった。
【0039】
【表4】
【0040】
表4から明らかなように、本発明品は優れた美白効果を示すことがわかる。特に、すでに皮膚美白作用のあることが知られているアスコルビン酸誘導体、胎盤抽出物配合例と比べても、本発明品が美白効果において優れていることが認められた。
【0041】
以下に、種々の剤型の本発明による美白用皮膚外用剤の配合例を、実施例として説明する。なお、植物抽出物の配合量は、乾燥残分量である。
【0042】
(製法)
(15)に(4)、(6)〜(10)を加え、加熱して70℃に保った(水相)。一方、(1)〜(3)、(5)、(11)〜(14)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却し、バニシングクリームを得た。
【0043】
(製法)
(17)に(9)〜(12)、(16)を加え加熱して70℃に保った(水相)。一方、(1)〜(8)、(13)〜(15)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却し、中性クリームを得た。
【0044】
(製法)
(13)に(8)、(10)、(11)および(12)を加え、加熱溶解して70℃に保った(水相)。一方、(1)〜(7)、(9)、(14)〜(17)を混合し、加熱融解して70℃に保った(油相)。水相に油相をかきまぜながら徐々の加え、反応を行った。反応終了後、ホモミキサーで均一に乳化し、乳化後よくかきまぜながら30℃まで冷却し、コールドクリームを得た。
【0045】
(製法)
(2)、(3)、(5)を50℃に昇温した後、(4)、(10)を加え完全に溶解した油相パーツに(1)を加えて均一に分散を行ったものに、(12)へ(6)、(7)、(8)、(11)を溶解させた水相パーツを50℃に加温して添加を行い、HMにて均一分散した後、室温まで冷却し、油中水型乳化組成物を得た。
【0046】
(製法)
(17)と(10)に、(16)および(7)を加温溶解し、さらに(6)、(8)、(9)、(11)〜(13)を溶解して、70℃に保った(水相)。一方、(1)〜(5)、(14)、(15)、(18)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0047】
(製法)
(17)と(10)に、(16)および(7)を加温溶解し、さらに(6)、(8)、(9)、(11)〜(13)、(15)を溶解して、70℃に保った(水相)。一方、(1)〜(5)、(14)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0048】
(製法)
(17)と(9)に、(15)、(16)および(6)を溶解し、さらに(5)、(7)、(8)、(10)〜(12)、(14)を溶解して、70℃に保った(水相)。一方、(1)〜(4)および(13)、(18)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0049】
(製法)
(15)に(13)を加熱溶解し、さらに(14)、(5)〜(10)を溶解して、70℃に保った(水相)。一方、(1)〜(4)、および(11)、(12)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一に乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0050】
(製法)
(12)に(7)、(9)および(10)、(16)を加え、加熱溶解して70℃に保った(水相)。また、(6)に(11)を加えて溶解した(アルコール相)。一方、(1)〜(5)、(8)(13)、(14)、(15)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した。これをかきまぜながらアルコール相を加えた。その後かきまぜながら30℃まで冷却し、乳液を得た。
【0051】
(製法)
(16)に(9)、(11)〜(14)を加え、加熱して70℃に保った(水相)。一方、(1)〜(8)、(10)、(15)、(17)〜(20)を混合し、加熱溶解して70℃に保った(油相)。油相をかきまぜながら、この油相に水相を徐々に加え、ホモミキサーで均一に乳化した。乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0052】
(製法)
(1)〜(8)を溶解し(油相)、(9)〜(16)を溶解し(水相)、油相に水相を添加し、乳化し、乳液を得た。
【0053】
(製法)
溶解した(B)相に、溶解した(A)相を添加し、乳化後、(C)相で中和し、乳液を得た。
【0054】
(製法)
(14)に(11)、(5)、(3)および(8)を均一に溶解した(水相)。一方、(1)に(2)、(4)、および(6)、(7)、(12)、(13)を溶解し、これを水相に添加した。次いで(9)、(10)で中和させ増粘して、ゼリーを得た。
【0055】
(製法)
80℃にて水相を調製し、50℃に冷却した。次いで室温で調製したアルコール相を添加後均一に混合し、放冷する。
【0056】
(製法)
室温にて水相を均一に調製した。ここに、室温にて調製したアルコール相を加し、均一に混合して粉末入りパックを得た。
【0057】
(製法)
(8)に(6)、(7)を加え、70℃に保った(水相)。一方、(1)〜(5)を70℃にて混合溶解した(油相)。水相に油相を添加し、ホモミキサーで均一に乳化後、冷却し、吸水軟膏を得た。
【0058】
(製法)
水相およびアルコール相をそれぞれ均一溶解後、アルコール相を水相に添加し、均一に混合した。
【0059】
(製法)
水相およびアルコール相をそれぞれ均一に溶解後、アルコール相を水相に添加し、均一に混合した。
【0060】
上記実施例9〜26の美白用皮膚外用剤はいずれも美白効果試験において優れた効果が認められた。
【0061】
【発明の効果】
以上詳述したように、本発明によれば、チロシナーゼ活性阻害効果およびサイクリックAMP(cAMP)産生阻害効果を併せ持ち、優れたメラニン生成抑制効果、美白効果を有する安全性の高い美白用皮膚外用剤が提供される。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a skin whitening external preparation containing a specific plant extract. The skin whitening preparation of the present invention has both a tyrosinase activity inhibitory effect and a cyclic AMP (cAMP) production inhibitory effect, has an excellent melanin production inhibitory effect, a whitening effect, and is excellent in safety.
[0002]
[Prior art]
Pigmentation, such as skin spots and freckles, is caused by abnormal secretion of hormones, ultraviolet rays, inflammatory stimuli, etc., which activates the melanin production signaling pathway in epidermal pigment cells, and produces and expresses tyrosinase, the main enzyme of melanin production. Is caused by excessive deposition of melanin on the epidermis.
[0003]
As means for preventing such spots and freckles, substances that inhibit the activity of tyrosinase, which is a major enzyme for producing melanin, have been conventionally used. Specifically, topical application of creams and lotions containing kojic acid, ellagic acid, etc., whose mechanism of action is to capture copper ions essential for tyrosinase activity expression, and a structure similar to the substrate tyrosine A topical application of creams, lotions and the like, which contain a hydroquinone derivative, a resorcinol derivative, etc., which acts as a tyrosinase competition inhibitor, or a substance having an action mechanism other than the above, dopaquinone which is a melanin precursor The administration of L-ascorbic acid has been carried out with the mechanism of suppressing melanin production by reducing to Dopa.
[0004]
[Problems to be solved by the invention]
The above substances act on the produced tyrosinase or on dopaquinone produced by expressing the tyrosinase activity, and do not inhibit the tyrosinase production itself. Therefore, there was a disadvantage that the effect itself and its persistence were weak. In addition, L-ascorbic acid has poor stability in the drug substance and the base, and a large amount of L-ascorbic acid is required to obtain an effect of sufficiently preventing spots and freckles.
[0005]
In recent years, various active ingredients contained in plant extracts have been receiving attention. Various actions such as an antitumor action, including an antioxidant action of polyphenols contained in many plants, have been reported. A variety of plant extracts having a whitening effect have been searched for.
As a plant having a whitening effect, Kinzakurako, Yomi, Jiyu and the like are conventionally known, and these plant extracts also have a mechanism of action that inhibits tyrosinase activity. And its persistence was not satisfactory.
On the other hand, as substances that act on the signal transduction pathway and inhibit melanin production itself, syrup having a nitric oxide pathway inhibiting action, chamomile having a protein kinase C pathway inhibiting action, and the like have been reported. However, these transmission pathways have a low involvement in melanin production, and it is difficult to obtain remarkable inhibition of melanin production. Therefore, development of better plant extract medicinal agents has been expected.
The present applicant has already found that roses of the family Rosaceae have a whitening effect by inhibiting the production of cyclic AMP (cAMP) (JP-A-2002-29959).
[0006]
The present inventors have conducted intensive studies in view of the above circumstances, and as a result, a specific plant and its extract have both an inhibitory effect on tyrosinase activity and an inhibitory effect on the adenylate cyclase pathway highly involved in melanin production, and have excellent whitening. The present invention was found to have an effect and an excellent melanin production inhibitory effect, and completed the present invention.
[0007]
[Means for Solving the Problems]
That is, the present invention relates to an azalea family such as Gaultheria fragrantissima, Oxalis family Averrhoa carambola (alias: Gorenshi), coconut family Cocos nucifera (alias: coconut, coconut), and an extract containing these effective components, such as those containing the effective components of the Desmodium of the legume family. It is a skin whitening agent for external use characterized by the following.
[0008]
The present invention also provides a melanin production inhibitor, a tyrosinase activity inhibitor, and a cyclic AMP (cAMP) production inhibitor, comprising the plant or a solvent extract thereof as an active ingredient.
[0009]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described in detail.
The azaleas used in the present invention include: Azalea Gaultheria fragrantissima, Oxalis Averrhoa carambola (alias: Gorrenshi), coconut palms Cocos nucifera (alias: coconut, coconut), and dried legumin, which can be used as it is, can be used as it is. Although it can be used, it is preferably used as a dry powder or a solvent extract from the viewpoint of usability, formulation and the like.
[0010]
Preferred sites of use for each plant are as follows.
That is, leaves and fruits for the azalea Gaultheria fragrantissima, leaves and fruits for the oxaceae Averrhoa carambola (alias: Gorrensi), roots for the cocos cocos nucifera (alias: coco palm, coconut), and roots of the legumes dari and tau are the roots of the legumes dari and tau, respectively. Although use is preferred, other sites can be used.
[0011]
The solvent extract of each of the above plants can be obtained by a conventional method. For example, it can be obtained by immersing or heating under reflux with an extraction solvent, followed by filtration and concentration. As the extraction solvent, any solvent can be used as long as it is a solvent usually used for extraction. For example, water, methanol, ethanol, propylene glycol, 1,3-butylene glycol, alcohols such as glycerin, hydrous alcohols, chloroform And organic solvents such as dichloroethane, carbon tetrachloride, acetone, ethyl acetate and hexane, etc., can be used alone or in combination. The extract obtained by extraction with the above solvent is used as it is, or the concentrated extract is adsorbed by an adsorption method, for example, one obtained by removing impurities using an ion exchange resin, or a column of a porous polymer (eg, Amberlite XAD-2). After that, elution with methanol or ethanol and concentration can also be used. In addition, a partitioning method, for example, an extract extracted with water / ethyl acetate and the like are also used.
[0012]
The plant extract thus obtained is highly safe and has excellent whitening effect, melanin production inhibitory effect, tyrosinase activity inhibitory effect, and cyclic AMP (cAMP) production inhibitory effect.
[0013]
When the above-mentioned plant extract is used in combination with an external preparation for skin, it is preferable to add 0.000001 to 5.0% by mass as a dry weight in the total amount of the external preparation, more preferably 0.00001 to 3.0% by mass. And particularly preferably 0.00001 to 1.0% by mass.
[0014]
When the plant extract is used in combination with a skin external preparation, in addition to these extracts, within the range not impairing the effects of the present invention, other components usually used in skin external preparations such as cosmetics and pharmaceuticals, for example, An oil, a wetting agent, an ultraviolet absorber, an antioxidant, a surfactant, a preservative, a humectant, a fragrance, water, alcohol, a thickener, and the like can be appropriately compounded as necessary.
[0015]
Examples of the ultraviolet absorbent described in the preceding paragraph include 2-hydroxy-4-methoxybenzophenone, sodium 2-hydroxy-4-methoxybenzophenone-5-sulfonate, sodium benzotriazolylbutylphenolsulfonate, and methylenebis-benzotriazoyltetramethylbutylphenol. Benzophenone derivatives, octyl paramethoxycinnamate, glyceryl mono-2-ethylhexanoate diparamethoxycinnamate, methoxycinnamic acid derivatives such as isopentyltrimethoxycinnamate trisiloxane, urocanic acid, 4-tert-4'-methoxydibenzoylmethane , Bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, phenylbenzimidazole sulfonic acid and the like can be appropriately compounded as necessary. .
[0016]
Furthermore, disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, sequestering agents such as gluconic acid, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice extract, Other drugs such as grabradine, various crude drugs, tocopherol acetate, glycyrrhizic acid and derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, glucoside ascorbate, arbutin, kojic acid, resorcinol, ellagic acid, chamomile extract, etc. Whitening agents, sugars such as glucose, fructose, mannose, sucrose, trehalose and the like can also be appropriately blended.
[0017]
Further, the external preparation for skin of the present invention can be widely applied to cosmetics, pharmaceuticals, quasi-drugs and the like, particularly preferably applied to cosmetics, which are applied to the outer skin. Any formulation that can be used, such as a solution system, a solubilizing system, an emulsifying system, a powder dispersing system, a water-oil two-layer system, a water-oil-powder three-layer system, an ointment, a gel, an aerosol, etc. Is applied.
[0018]
The form of use of the external preparation for skin of the present invention is also optional. For example, it can be used for facial cosmetics such as lotions, emulsions, creams, packs and foundations, makeup cosmetics, aromatic cosmetics, bath preparations and the like. it can.
The form that the external preparation for skin of the present invention can take is not limited to the above-mentioned dosage form and use form.
[0019]
【Example】
Next, the present invention will be described in more detail with reference to examples, but the technical scope of the present invention is not limited by these examples. In addition, all compounding amounts are mass%.
[0020]
Prior to the examples, test methods and evaluation methods for the tyrosinase activity inhibitory effect, cyclic AMP (cAMP) production inhibitory effect, melanin production inhibitory effect, and whitening effect of the plant extract of the present invention will be described.
[0021]
[Test method and evaluation method]
1. Preparation of Sample (1) Extract of Gaultheria fragrantissima extract 1000 g of leaves of Gaultheria fragrantissima extract was heated and extracted with 5 L of 80% ethanol to obtain an extract. This extract was concentrated to obtain 72.0 g of Gaultheria fragrantissima extract.
[0022]
(2) Averrhoa carambola extract 50 g of leaves of Averrhoa carambola were extracted at room temperature with 1 L of 80% ethanol to obtain an extract. The extract was concentrated to obtain 7.3 g of Averrhoa carambola extract.
[0023]
(3) Cocos nucifera extract 50 g of Cocos nucifera root was extracted at room temperature with 1 L of 80% ethanol to obtain an extract. The extract was concentrated to obtain 2.3 g of Cocos nucifera extract.
[0024]
(4) Desmodium triquerum extract Extract 50 g of leaves of Desmodium triquerum was extracted at room temperature with 1 L of 80% ethanol to obtain an extract. This extract was concentrated to obtain 3.5 g of Desmodium triquentrum extract.
[0025]
Each of the above plant extracts was dissolved in 70% ethanol to a concentration of 2% by mass to obtain a plant extract-containing solution. The concentration of the plant extract-containing solution was adjusted by diluting the solution, and this was used as a sample solution, and the following experiment was performed.
[0026]
2. Cell culture method B16 melanoma cultured cells derived from mice were used. 37 ° C. in a CO 2 incubator (95% air, 5% carbon dioxide) in Dulbecco's MEM medium containing 10% FBS and theophylline (0.09 mg / ml) or melanocyte stimulating hormone (α-MSH) (10 nM). Cultured underneath.
[0027]
3. Measurement of Tyrosinase Activity Inhibitory Effect The cells cultured by the above method 2 were seeded on a 96-plate, and after 24 hours of culture, the sample solution was adjusted so that the final concentration (concentration in terms of dry extract) was 10 −7 to 10 −5 mass%. Was added and the culture was continued. After 3 days of culture, the cells were washed with PBS, PBS containing 1% Triton was added, and DOPA was further added to a final concentration of 1 mM. The absorbance (475 nm) was measured at 0 and 60 minutes after the addition. It was compared with a sample to which no plant extract was added (control; 70% ethanol) and evaluated according to the following criteria. In addition, as a reference example, a test similar to the above was performed on a novara (Rosa canina L.) extract (ethanol extraction). Table 1 shows the results. Table 1 shows the results in a medium containing melanocyte stimulating hormone (α-MSH). Similar results were obtained when theophylline was used.
[0028]
(Judgment criteria)
:: Excellent in tyrosinase activity inhibitory effect as compared to control.
Δ: Slightly superior to tyrosinase activity inhibitory action compared to control.
X: No tyrosinase activity inhibitory action.
[0029]
[Table 1]
[0030]
4. Visual judgment of melanin amount (melanin production suppression effect)
The cells cultured by the above method 2 are seeded on a 96-plate, and after 24 hours of culture, a sample solution is added so that the final concentration (concentration in terms of dry extract) becomes 10 −2 to 10 −5 mass%. Continued. After 3 days of culture, a diffusion plate was placed on the lid of a 96-well plate, the amount of melanin in the cells was observed with an inverted microscope, and compared with a sample without added plant extract (control; 70% ethanol). Evaluation was made according to the following criteria. In addition, as a reference example, a test similar to the above was performed on a novara (Rosa canina L.) extract (ethanol extraction). Table 2 shows the results. Table 2 shows the results in a medium containing melanocyte stimulating hormone (α-MSH). The same results were obtained when theophylline was used.
[0031]
(Judgment criteria)
:: Whiter than control (excellent in melanin production inhibitory action).
Δ: slightly whiter than control (slightly superior in melanin production inhibitory action).
X: Whiteness comparable to that of the control (no melanin production inhibitory action).
[0032]
[Table 2]
[0033]
5. Cyclic AMP (cAMP) production inhibitory effect measurement B16 melanoma cultured cells derived from mice were seeded in a 12-well plate, and in a CO 2 incubator (95% air, 5% carbon dioxide) in Dulbecco's MEM medium containing 10% FBS, 37%. The culture was performed under the condition of ° C. After culture for 24 hours, the medium was aspirated, and melanocyte stimulating hormone (α-MSH, 0.1 nM) and a sample solution were added to a final concentration of 10 −1 to 10 −3 mass% (concentration in terms of dry extract). Serum-free medium was added. After incubating for 30 minutes, the medium was removed, the cells were collected with TE buffer, transferred to a 1.5 mL microtube, boiled, and the amount of cyclic AMP (cAMP) in this solution was measured using a cyclic AMP (cAMP) measurement kit. (Manufactured by Amersham). In addition, as a reference example, a test similar to the above was performed on an extract of rose (Rosa canina L.) belonging to the genus Rosaceae (Rosa), which was extracted with ethanol. It was compared with a sample to which no plant extract was added (control; 70% ethanol) and evaluated according to the following criteria. Table 3 shows the results.
[0034]
(Judgment criteria)
:: Excellent in cyclic AMP (cAMP) production inhibitory effect as compared with control.
Δ: Slightly superior to cyclic AMP (cAMP) production inhibitor action as compared to control.
×: No cyclic AMP (cAMP) production inhibitory action.
[0035]
[Table 3]
[0036]
6. Whitening effect test (test method)
The following test sample solutions were applied to the back skin of 20 subjects exposed to the sunlight of summer for 4 hours (2 hours a day for 2 days) once every morning and evening for 4 weeks, and the following criteria Was evaluated. Table 4 shows the results of the average value of the evaluation points of the 20 subjects.
[0037]
(Production method)
After preparing the aqueous phase and the alcohol phase, they were mixed and solubilized.
[0038]
(Evaluation method)
The lightening effect after use was determined based on the following criteria.
(Score)
4: After continuous application, a lightening effect was remarkably observed.
3: After continuous application, a lightening effect was observed.
2: After continuous application, lightening effect was slightly recognized.
1: No lightening effect was observed after continuous application.
[0039]
[Table 4]
[0040]
As is clear from Table 4, the product of the present invention shows an excellent whitening effect. In particular, it was confirmed that the product of the present invention is superior in whitening effect even in comparison with ascorbic acid derivatives and placental extract formulations already known to have a skin whitening effect.
[0041]
Examples of the formulation of skin whitening external preparations of the present invention in various dosage forms will be described below as examples. In addition, the compounding quantity of a plant extract is a dry residue amount.
[0042]
(Production method)
(4) and (6) to (10) were added to (15), and the mixture was heated and maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (3), (5), (11) to (14) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to carry out preliminary emulsification, and after uniform emulsification with a homomixer, the mixture was cooled to 30 ° C. while stirring well to obtain a burnishing cream.
[0043]
(Production method)
(17), (9) to (12) and (16) were added, and the mixture was heated and maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (8) and (13) to (15) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to carry out preliminary emulsification, and after uniform emulsification with a homomixer, the mixture was cooled to 30 ° C. while stirring well to obtain a neutral cream.
[0044]
(Production method)
(8), (10), (11) and (12) were added to (13), and the mixture was dissolved by heating and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (7), (9) and (14) to (17) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The reaction was carried out by gradually adding the oil phase to the aqueous phase while stirring. After completion of the reaction, the mixture was uniformly emulsified with a homomixer, cooled to 30 ° C. while stirring well after emulsification, and a cold cream was obtained.
[0045]
(Production method)
After heating (2), (3) and (5) to 50 ° C, (4) and (10) were added, and (1) was added to the completely dissolved oil phase parts to perform uniform dispersion. Then, the aqueous phase parts in which (6), (7), (8), and (11) are dissolved are added to (12) by heating to 50 ° C., uniformly dispersed with HM, and then to room temperature. After cooling, a water-in-oil emulsion composition was obtained.
[0046]
(Production method)
(16) and (7) are dissolved by heating in (17) and (10), and (6), (8), (9) and (11) to (13) are further dissolved. Kept (aqueous phase). On the other hand, (1) to (5), (14), (15), and (18) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0047]
(Production method)
(16) and (7) are dissolved by heating in (17) and (10), and (6), (8), (9), (11) to (13) and (15) are further dissolved. , 70 ° C (aqueous phase). On the other hand, (1) to (5) and (14) were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0048]
(Production method)
Dissolve (15), (16) and (6) in (17) and (9) and further dissolve (5), (7), (8), (10)-(12) and (14) And maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (4) and (13) and (18) were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0049]
(Production method)
(13) was dissolved in (15) by heating, and (14) and (5) to (10) were further dissolved and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (4), and (11) and (12) were mixed, heated and melted, and kept at 70 ° C (oil phase). The oil phase was added to the water phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0050]
(Production method)
(7), (9) and (10) and (16) were added to (12), and the mixture was dissolved by heating and maintained at 70 ° C. (aqueous phase). Further, (11) was added to (6) and dissolved (alcohol phase). On the other hand, (1) to (5), (8), (13), (14), and (15) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to perform preliminary emulsification, and the mixture was uniformly emulsified with a homomixer. The alcohol phase was added while stirring this. Thereafter, the mixture was cooled to 30 ° C. while stirring to obtain an emulsion.
[0051]
(Production method)
(9) and (11) to (14) were added to (16), and the mixture was heated and maintained at 70 ° C (aqueous phase). On the other hand, (1) to (8), (10), (15), (17) to (20) were mixed, dissolved by heating, and kept at 70 ° C. (oil phase). While stirring the oil phase, the water phase was gradually added to the oil phase, and the mixture was uniformly emulsified with a homomixer. After emulsification, the mixture was cooled to 30 ° C. while stirring well to obtain an emulsion.
[0052]
(Production method)
(1) to (8) were dissolved (oil phase), (9) to (16) were dissolved (aqueous phase), and the aqueous phase was added to the oil phase and emulsified to obtain an emulsion.
[0053]
(Production method)
The dissolved (A) phase was added to the dissolved (B) phase, emulsified, and then neutralized with the (C) phase to obtain an emulsion.
[0054]
(Production method)
(11), (5), (3) and (8) were uniformly dissolved in (14) (aqueous phase). On the other hand, (2), (4), and (6), (7), (12), and (13) were dissolved in (1), and this was added to the aqueous phase. Next, the mixture was neutralized and thickened by (9) and (10) to obtain jelly.
[0055]
(Production method)
An aqueous phase was prepared at 80 ° C and cooled to 50 ° C. Next, the alcohol phase prepared at room temperature is added, mixed uniformly, and left to cool.
[0056]
(Production method)
The aqueous phase was uniformly prepared at room temperature. Here, the alcohol phase prepared at room temperature was added and mixed uniformly to obtain a powder-containing pack.
[0057]
(Production method)
(6) and (7) were added to (8), and the mixture was maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (5) were mixed and dissolved at 70 ° C. (oil phase). The oil phase was added to the water phase, uniformly emulsified with a homomixer, and then cooled to obtain a water-absorbing ointment.
[0058]
(Production method)
After uniformly dissolving the aqueous phase and the alcohol phase, the alcohol phase was added to the aqueous phase and mixed uniformly.
[0059]
(Production method)
After uniformly dissolving the aqueous phase and the alcohol phase, the alcohol phase was added to the aqueous phase and mixed uniformly.
[0060]
All of the skin whitening external preparations of Examples 9 to 26 showed excellent effects in the whitening effect test.
[0061]
【The invention's effect】
INDUSTRIAL APPLICABILITY As described above in detail, according to the present invention, a highly safe skin whitening preparation having both a tyrosinase activity inhibitory effect and a cyclic AMP (cAMP) production inhibitory effect, an excellent melanin production inhibitory effect, and a whitening effect. Is provided.